- Home
- KGS vs ARQT Comparison
KGS vs ARQT Comparison
Compare KGS & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KGS | ARQT |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KGS | ARQT |
|---|---|---|
| Price | $37.06 | $29.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $43.00 | $24.83 |
| AVG Volume (30 Days) | 1.8M | ★ 2.0M |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | ★ 224.29 | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $1,284,748,000.00 | $317,929,000.00 |
| Revenue This Year | $13.95 | $85.51 |
| Revenue Next Year | $7.27 | $30.74 |
| P/E Ratio | $43.54 | ★ N/A |
| Revenue Growth | 19.43 | ★ 129.21 |
| 52 Week Low | $29.25 | $11.13 |
| 52 Week High | $50.43 | $31.77 |
Technical Indicators
Market Signals| Indicator | KGS | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 58.93 | 56.39 |
| Support Level | $35.19 | $27.55 |
| Resistance Level | $38.27 | $28.90 |
| Average True Range (ATR) | 1.01 | 1.18 |
| MACD | -0.00 | -0.35 |
| Stochastic Oscillator | 68.59 | 43.67 |
Price Performance
Historical ComparisonAbout KGS Kodiak Gas Services Inc.
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Contract Services and Other Services. Contract Services consists of operating Company-owned and customer-owned compression, and gas treating and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.